Omid Zargari, MD, IFAAD
Senior Consultant Dermatologist
Office: DANA clinic, Golsar, Rasht 4163793737, Iran,
Phone: +98 13 3211 7520, 13 3212 3438
Websites: www.iranderma.com
www.drzargari.com
Birth: 1967
2004-present: Consultant Dermatologist, DANA Clinic, Rasht, Iran
2002-04: Assistant professor of Dermatology, Guilan University of Medical Sciences, Rasht, Iran
1999-2002: Working in Guilan Research center for skin diseases, Rasht, Iran
1999: Iranian Board of Dermatology
1995-99: Resident, Department of Dermatology, National University of Iran, Tehran, Iran
1985-92: MD, National University of Iran (Shahid Beheshti University of Medical Sciences), Tehran, Iran
Memberships:
Iranian Medical Council, since 1992
Iranian Society of Dermatology, since 1999
International Society of Dermatology (ISD), since 2002
International Society of Dermatoscopy, since 2004
International Society of Teledermatology, since 2004
European Academy of Dermatology and Venereology (EADV), since 2005
American Academy of Dermatology (AAD), since 2008
Councilor of International Psoriasis Council (IPC), since 2015
Editorial activities:
§ Reviewer for Scientific publications of various Dermatology Journals.
§ Member-Editorial Board, Journal of Dermatology and Cosmetic
§ Member-Editorial Board, Iranian Journal of Dermatology
§ Member-Editorial Board, Indian Journal of Dermatology
§ Member-Editorial Board, The Online Journal of Community and Person-Centered Dermatology (OJCPCD)
Lectures:
§ Delivered more than 200 lectures in various national and international dermatology meetings.
Awards & Grants:
· Guilan University of Medical Sciences Best researcher of the year 2003.
· European Academy of Dermatology and Venereology Education grant for the 13th EADV congress. Florence, Italy 2004.
· European Academy of Dermatology and Venereology Education grant for the 14th EADV congress. London, United Kingdom 2005.
· Imrich Sarakany Non- European Exceptional Cases Grant. European Academy of Dermatology and Venereology. Rhodes, Greece 2006
Publications (In English):
1. Golchai J., Zargari O., Sabouri M.R. Multiple Apocrine Hydrocystomas; Photoclinic. Archives of Iranian Medicine 2003 ; 6:225-7
2. Zargari O., Kimyai-Asadi A., Fathalikhani F., Panahi M. Paederus dermatitis in northern Iran: a report of 156 cases. Int J Dermatol 2003;42(8):608-12
3. Zargari O. Disseminated granuloma faciale. Int J Dermatol, 2004 Mar;43(3):210-12.
4. Golchai J., Zargari O., Maboudi A. Lepromatous leprosy with extensive unusual ulcerations and cachexia. Is it the first case of Lucio’s phenomenon from Iran? International Journal of Leprosy. 2004 Mar;72(1):56-9
5. Zargari O., Kimyai-Asadi A., Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia. Pediatric dermatology 2004;21(6):633-5
6. Golchai J., Zargari O., Paknejadi M.B. Multiple granular cell tumor in a teenager: report of a case and review of the literature. Acta Medica Iranica 2004;42(3):228-31
7. Zargari O., Hoda S., Golchai J., Asgari K. Nodular hydradenoma; Photoclinic. Archives of Iranian Medicine 2005 ; 8:150-3
8. Zargari O. Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis. Dermatol online J. 2005;11 (3):21
9. Zargari O, Hoda S. Eosinophilic Cellulitis: Report of a case and literature review. Iran J Dermatol. 2005; 8
10. Zargari O., Golchai J., Sobhani A., Dehpour A.R. Comparison of the efficacy of topical lindane 1% vs 5% permethrin in scabies: A randomized, double-blind study. Indian J Dermatol Venereol Lepreol 2006; 72:33-6
11. Zargari O. The prevalence and significance of fissured tongue and geographic tongue in psoriatic patients. Clin Exp Dermatol 2006; 31: 192-5
12. Zargari O. Exclusive penile Kaposi’s sarcoma: report of an HIV-negative male successfully treated with radiotherapy. J Eur Acad Dermatol Venereol 2006; 20: 318-20
13. Zargari O., Kimyai-Asadi A. Attitudes of Iranian patients with skin problems towards using the Internet as a medical resource. Int J Dermatol. 2006; 45:535-7
14. Zargari O. Methotrexate, hyperosmia, and migraine. Dermatol online J. 2006 10;12(7):28
15. Zargari O. Pentoxifylline: A drug with wide spectrum applications in dermatology. Dermatol Online J. 2008 Nov 15;14(11):2.
16. Zargari O., Gorouhi F. Successful Treatment of Earlobe Keloids with Imiquimod after Shave Excision. Iran J Dermatol. 2009; 12: 31-32
Jafroodi M, Zargari O, Hoda S. Concomitant Hodgkin's lymphoma and atopic dermatitis in a child with Celiac disease. Arch Iran Med
18. Sockolov ME, Alikhan A, Zargari O. Non-psoriatic dermatologic uses of monoclonal antibody therapy. J Dermatology Treat. 2009; 20(6):319-27
19. Zargari O, Elpern DJ. Granulomatous diseases of the nose. Int J Dermatol. 2009;48:1275-82
20. Alikhan A, Burns T, Zargari O. Punctate porokertotic keratoderma. Dermatol Online J. 2010: 15;16(1):13.
21. Alikhan A, Gorouhi F, Zargari O. Fox- Fordyce Disease exacerbated by hyperhidrosis. Pediatr Dermatol. 2010:;27(2):162-5.
22. Pirouzi S, Alikhan F, Zargari O. Goltz syndrome: a case report from Iran. Iranian J Dermatol. Vol. 15, No. 60, Summer 2012
23. Zargari O., Hejazi S., Shahidi-dadras M et al. Considerable variation among Iranian dermatologists in the dosing and monitoring of methotrexate for treating psoriasis. Int J Dermatol. 2014 Mar;53(3):385-9. doi: 10.1111/ijd.12201
24. Askari K, Seyed Saadat SN, Seyed Saadat SM, Yousefi N, Ghorbani G, Zargari O. Cutaneous botryomycosis caused by Staphylococcus aureus in a patient with diabetes. Int J Dermatol. 2014 Apr;53(4):413-5. doi: 10.1111/ijd.12325
25. Askari K, Ghorbani G, Yousefi N, Saadar SM, Saadat SN, Zargari O. Chondroid syringoma of the forearm: a case report of a rare localization. Indian J Dermatol. 2014 Sep; 59(5):507-9. doi: 10.4103/0019-5154.139914.
26. Kesty K, Zargari O. Eruptive blue nevi. Indian J Dermatol Venereol Leprol. 2015 Mar-Apr;81(2):198-201. doi: 10.4103/0378-6323.152302.
27. Zargari O. Radiation-induced basal cell carcinoma. Dermatol Pract Concept. 2015 Apr 30;5(2):109-12.
28. Shahidi-Dadras M, Haghighatkhah HR, Abdollahimajd F, Younespour S, Partovi Kia M, Zargari O. Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis. Int J Dermatol. 2015 Jul 1. doi: 10.1111/ijd.12842.
29. Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermecin in dermatology. Dermatol Online J. 2016; 15:22(9)
30. Azimi SZ, Zargari O, Rudolph RI. Nodular colloid milium mimicking keloid. J Cosmet Dermatol. 2017 Mar 9. doi: 10.1111/jocd.12325
31. Zargari O, Azimi SZ, Geranmayeh S. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib. Dermatol Ther. 2017 Jun 19. doi: 10.1111/dth.12509.
32. Youssefian L, Touati A, Saeidian AH, Zargari O, Zeinali S, Vahidnezhad H, Uitto J. A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome. Orphanet J Rare Dis. 2017 Dec 6;12(1):176. doi: 10.1186/s13023-017-0728-8.
33. Pirouzi S, Zargari O, Kamyab K, Kesty K. Perforating necrobiosis lipoidica. Iran J Dermatol. 2017; 20: 89-92
34. Pishgahi M, Dadkhahfar S, Robati RM, Kheradmand Z, Shahidi-Dadras M, Zargari O, Elpern DJ. Electrocardiographic changes after high dose corticosteroid pulse therapy in pemphigus patients. J Dermatolog Treat. 2018 Apr 18:1-14. doi: 10.1080/09546634.2018.1466980.
35. Zargari O, Azimi SZ, Geranmayeh S. Giant clear cell acanthoma with dermoscopic white lines. Dermatol Pract Concept. 2018 Jul 31;8(3):245-247. doi: 10.5826/dpc.0803a18. eCollection 2018 Jul.
36. Zargari O, Leyli EK, Azimi SZ. Nail involvement in patients with psoriatic arthritis in northern Iran. Autoimmune Dis. 2018 Oct 15; 2018:4608490. doi: 10.1155/2018/4608490. eCollection 2018.
37. Shahidi-Dadras M, Niknezhad N, Niknejad N, Zargari O. Can serum level of N-terminal pro B-type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease? Dermatol Ther. 2019 Mar 5:e12865. doi: 10.1111/dth.12865.
38. Zargari O, Azimi SZ, Barat T, Lajevardi V, Kazemnezhad E, Shahidi-Dadras M. Comorbidities in Iranian obese psoriatic patients compared with non-obese patients. Acta Med Iran 2019; 57: (4): 253-261.
39. Almasi-Nasrabadi M, Robati RM, Zargari O, Shahidi-Dadras M. Considerable variation among Iranian dermatologists in the knowledge and attitudes regarding the use of biologic agents to manage psoriasis. Int J Womens Dermatol. 2019 Nov 7;5(5):356-360. doi: 10.1016/j.ijwd.2019.09.010. eCollection 2019 Dec.
40. Ghalamkarpour F, Baradaran-Rafii A, Sadoughi MM, Abdollahimajd F, Younespour S, Zargari O, Rudolph RI. Ocular findings in patients with psoriasis: Is it related to the side effects of treatment or to psoriasis itself? A case-control study. J Dermatolog Treat. 2020 Feb;31(1):27-32. doi:10.1080/09546634.2019.1577947. Epub 2019 Mar 1.PMID: 30704324
41. Niknezhad N, Haghighatkhah HR, Zargari O, Ghalamkarpour F, Younespour S, Niknejad N, Alikhan A, Abdollahimajd F. High sensitive C-reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis. Dermatol Ther. 2020 May 19. doi: 10.1111/dth.13628. Online ahead of print. PMID: 32431027
42. Zargari O, Azimi SZ. Fox-Fordyce disease: a side effect of laser therapy. J Cosmet Laser Ther. 2020 Jun 7:1-2. doi: 10.1080/14764172.2020.1774062
43. Shahidi-Dadras M, Zargari O, Abolghasemi R, Bahmanjahromi A, Abdollahimajd F. A probable atypical skin manifestation of COVID-19 infection. J Dermatolog Treat. 2020 Jul 13:1-3. doi: 10.1080/09546634.2020.1791309.
44. Ghalamkarpour F, Pourani MR, Abdollahimajd F, Zargari O. A case of severe psoriatic erythroderma with COVID-19. J Dermatolog Treat. 2020 Jul 21:1-11. doi: 10.1080/09546634.2020.1799918.
45. Zargari O. COVID-19: The new great imitator? Iranian J Dermatol. 2020:Vol. 23, Suppl.1(COVID-19): 1
46. Zargari O, Asadi M, Azimi SZ, Mesbah A. Rhabdomyomatous mesenchymal hamartoma presenting as telangiectasia in a 57-year-old man. J Cutan Pathol. 2021 May 8. doi: 10.1111/cup.14044.
47. Pourani MR, Abdollahimajd F, Zargari O, Shahidi-Dadras M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J Dermatolog Treat. 2021 Aug 7:1-27. doi: 10.1080/09546634.2021.1966357
48. Dadkhahfar S, Ohadi L, Rahimi Y, Robati RM, Shekarabi M, Zargari O, Shahidi-Dadras M. Patients’s perception, and adherence to treatment with biosimilar adalimumab in psoriasis. Dermatol Ther. 2021 Nov 25. doi: 10.1111/dth.15227.
49. Mahil SK, Dand N, Mason KJ, Yiu ZZN, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. Allergy Clin Immunol 2021 Jan; 147(1):60-71.
50. van Huizen AM, Menting SP, Gyulai R, Iversen L, et al. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatol. 2022 Mar
51. Vahidnezhad H, Youssefian L, Harvey N, Tavasoli AR, Saeidian AH, Sotoudeh S, Varghaei A, Mahmoudi H, Mansouri P, Mozafari N, Zargari O, Zeinali S, Uitto J. Mutation Update: The Spectra of PLEC Sequence Variants and Related Plectinopathies. Hum Mutat. 2022 Jul 11. doi: 10.1002/humu.24434.
Books: (As a contributor)
1. Osler’s Bedside Library: great writers who inspired a great physician. Philadelphia, PA, American College of Physicians Press, 2009. ISBN-13: 978-1-9344-6547-9
2. A Treatise on Topical Corticosteroids in Dermatology. Springer Nature Singapore Pte. Ltd., 2018. ISBN 978-981-10-4609-4